BOOG 13-08 shows skipping sentinel lymph node biopsy in patients 50+ with early-stage, hormone receptor–positive, ...
AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...
Radiation has been a staple of breast cancer treatment for decades, but a new study is casting doubt on whether it is ...
Verywell Health on MSN
Can an armpit lump be a symptom of breast cancer?
An armpit lump, also called axillary lump, can be a symptom of breast cancer. A healthcare provider should check any hard ...
AstraZeneca & Daiichi Sankyo’s Enhertu gets US FDA breakthrough therapy designation in US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer ...
UK pharma major AstraZeneca and Japan’s Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough ...
Adjuvant abemaciclib combined with endocrine therapy (ET) has demonstrated a statistically significant and clinically ...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
Cambridge: AstraZeneca and Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with ...
ENHERTU ® (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for adult patients with HER2 positive early breast cancer with residual invasive disease in the ...
AstraZeneca reports a Phase 3 lung cancer miss, FDA breakthrough status for Enhertu, and a $2 billion KRAS drug deal with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback